Literature DB >> 16626751

Predicting neuropsychological abnormalities in multiple sclerosis.

Ralph H B Benedict1, Robert Zivadinov.   

Abstract

Multiple Sclerosis (MS) is associated with MRI signal alteration and neuropsychological (NP) dysfunction. Screening tools have been developed to identify patients at high risk for these neurological complications of MS. One such measure, the Multiple Sclerosis Neuropsychological Screening Questionnaire (MSNQ), has well-established reliability and predictive validity. In this article, we report on the accumulated findings derived from 162 consecutive research participants and MS clinic attendees. Our data show significant correlation between both patient- and informant-report MSNQ and NP impairment. As shown previously, larger, and more significant correlations are found between informant-report MSNQs than with patient-report MSNQs. In addition, we find that the MSNQ predicts follow-up NP testing 51 weeks after baseline with a similar degree of association. Finally, the MSNQ is correlated with MRI measures of whole-brain lesion burden and atrophy, secondary progressive course, and vocational disability. We conclude that the MSNQ is reliable and valid for detecting neuropsychological and neuropsychiatric complications of MS.

Entities:  

Mesh:

Year:  2006        PMID: 16626751     DOI: 10.1016/j.jns.2005.05.020

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  19 in total

1.  A randomized controlled trial of a cognitive rehabilitation intervention for persons with multiple sclerosis.

Authors:  Alexa K Stuifbergen; Heather Becker; Frank Perez; Janet Morison; Vicki Kullberg; Ana Todd
Journal:  Clin Rehabil       Date:  2012-02-02       Impact factor: 3.477

2.  Decreased frontal lobe gray matter perfusion in cognitively impaired patients with secondary-progressive multiple sclerosis detected by the bookend technique.

Authors:  R I Aviv; P L Francis; R Tenenbein; P O'Connor; L Zhang; A Eilaghi; L Lee; T J Carroll; J Mouannes-Srour; A Feinstein
Journal:  AJNR Am J Neuroradiol       Date:  2012-04-26       Impact factor: 3.825

Review 3.  Reliability and validity of neuropsychological screening and assessment strategies in MS.

Authors:  Ralph H B Benedict; Robert Zivadinov
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

4.  Restless legs syndrome, sleep quality, and perceived cognitive impairment in adults with multiple sclerosis.

Authors:  Katie L J Cederberg; Brenda Jeng; Jeffer E Sasaki; Robert W Motl
Journal:  Mult Scler Relat Disord       Date:  2020-05-18       Impact factor: 4.339

5.  Robust perfusion deficits in cognitively impaired patients with secondary-progressive multiple sclerosis.

Authors:  P L Francis; R Jakubovic; P O'Connor; L Zhang; A Eilaghi; L Lee; T J Carroll; J Mouannes-Srour; A Feinstein; R I Aviv
Journal:  AJNR Am J Neuroradiol       Date:  2012-06-14       Impact factor: 3.825

6.  Cortical Perfusion Alteration in Normal-Appearing Gray Matter Is Most Sensitive to Disease Progression in Relapsing-Remitting Multiple Sclerosis.

Authors:  S-P Hojjat; M Kincal; R Vitorino; C G Cantrell; A Feinstein; L Zhang; L Lee; P O'Connor; T J Carroll; R I Aviv
Journal:  AJNR Am J Neuroradiol       Date:  2016-03-24       Impact factor: 3.825

7.  Screening Instruments for the Early Detection of Cognitive Impairment in Patients with Multiple Sclerosis.

Authors:  Sonya Kim; Vance Zemon; Joseph F Rath; MaryAnn Picone; Elizabeth S Gromisch; Heather Glubo; Lucia Smith-Wexler; Frederick W Foley
Journal:  Int J MS Care       Date:  2017 Jan-Feb

8.  Increased cerebral activation after behavioral treatment for memory deficits in MS.

Authors:  Nancy D Chiaravalloti; Glenn Wylie; Victoria Leavitt; John Deluca
Journal:  J Neurol       Date:  2012-01-12       Impact factor: 4.849

9.  Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study.

Authors:  Sarah A Morrow; Audrey Smerbeck; Kara Patrick; Diane Cookfair; Bianca Weinstock-Guttman; Ralph H B Benedict
Journal:  J Neurol       Date:  2012-09-23       Impact factor: 4.849

10.  Ginkgo biloba does not improve cognitive function in MS: a randomized placebo-controlled trial.

Authors:  Jesus F Lovera; Edward Kim; Elizabeth Heriza; Mary Fitzpatrick; James Hunziker; Aaron P Turner; Joshua Adams; Thomas Stover; Adam Sangeorzan; Alicia Sloan; Diane Howieson; Katherine Wild; Jodie Haselkorn; Dennis Bourdette
Journal:  Neurology       Date:  2012-09-05       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.